Capricorn Healthcare makes follow-on investment in HeartFlow
Capricorn Healthcare announced that it participated in the Series E financing of HeartFlow, Inc. ("HeartFlow"), a medical technology company. As reported by HeartFlow, the financing secured $240 million for the company and was led by Wellington Management and Baillie Gifford & Company. HeartFlow will use the proceeds from this financing to ramp up commercial expansion of the HeartFlow® FFRct Analysis, continued technology innovation, and additional clinical studies.
Based in Redwood City, CA, HeartFlow offers a non-invasive technology that creates a personalized 3D model of the heart and simulates blood flow to help clinicians diagnose and treat patients with suspected heart disease. To date, the HeartFlow Analysis has been used by clinicians at more than 80 medical institutions around the globe to diagnose and treat more than 15,000 patients. The Company seeks to transform how cardiovascular disease, the leading cause of death globally, is treated in a more efficient, cheaper, and more accurate way. Today, more than 185 million people in the US have insurance coverage for the HeartFlow Analysis.